| |
Total N (%*)
|
Cancer status
|
p-value**
|
|---|
|
Cancer N (%a)
|
No cancer N (%a)
|
|---|
|
N
|
555 (100)
|
49 (100)
|
506 (100)
| |
|
Nodule size
|
535 (100)
|
48 (100.0)
|
487 (100.0)
|
0.176
|
|
< 1 cm
|
27 (5.1)
|
5 (10.4)
|
22 (4.5)
|
|
1 – < 2 cm
|
174 (32.5)
|
17 (35.4)
|
157 (32.2)
|
|
2–4 cm
|
222 (41.5)
|
20 (41.7)
|
202 (41.5)
|
|
> 4 cm
|
112 (20.9)
|
6 (12.5)
|
106 (21.8)
|
|
Echogenicity
|
531 (100)
|
47 (100.0)
|
484 (100.0)
|
0.025
|
|
Cystic
|
15 (2.8)
|
1 (2.1)
|
14 (2.9)
|
|
Complex
|
287 (54.1)
|
17 (36.2)
|
270 (55.8)
|
|
Hyper-echoic
|
18 (3.4)
|
4 (8.5)
|
14 (2.9)
|
|
Hypo-echoic
|
124 (23.4)
|
17 (36.2)
|
107 (22.1)
|
|
Isoechoic
|
87 (16.4)
|
8 (17.0)
|
79 (16.3)
|
|
Calcification
|
547 (100)
|
48 (100.0)
|
499 (100.0)
|
< 0.001
|
|
Coarse
|
25 (4.6)
|
14 (29.2)
|
11 (2.2)
|
|
Yes
|
125 (22.9)
|
10 (20.8)
|
115 (23.0)
|
|
No
|
397 (72.6)
|
24 (50.0)
|
373 (74.8)
|
|
Lymphadenopathy
|
554 (100)
|
49 (100)
|
505 (100)
|
0.999
|
|
No
|
530 (95.7)
|
47 (95.9)
|
483 (95.6)
|
|
Yes
|
24 (4.3)
|
2 (4.1)
|
22 (4.4)
|
|
FNA Cytology
|
551 (100)
|
49 (100)
|
502 (100)
|
< 0.001
|
|
Bethesda, I
|
29 (5.3)
|
1 (2.0)
|
28 (5.6)
|
|
Bethesda II
|
435 (79.0)
|
4 (8.2)
|
431 (85.9)
|
|
Bethesda III
|
32 (5.8)
|
6 (12.2)
|
26 (5.2)
|
|
Bethesda IV
|
25 (4.5)
|
17 (34.7)
|
8 (1.6)
|
|
Bethesda V
|
16 (2.9)
|
12 (24.5)
|
4 (0.8)
|
|
Bethesda VI
|
14 (2.5)
|
9 (18.4)
|
5 (1.0)
|
- aColumn percent. **p-value comparing cancerous vs noncancerous groups
- (20, 24, 8, 1, & 4 nodules were missing size, echogenicity, calcification, lymphadenopathy, & FNA cytology information, respectively)
